gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 04 Oct 2015.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Interleukin-6: Biology, signaling and strategies of blockade.
Rose-John et al., Magdeburg, Germany. In Cytokine Growth Factor Rev, 31 Oct 2015
While classic IL-6 signaling via the membrane bound receptor is mainly regenerative and protective, IL-6 trans-signaling via the soluble IL-6R is rather pro-inflammatory.
Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and Is Essential for Its Shedding Activity.
Lorenzen et al., Kiel, Germany. In Biochemistry, 29 Oct 2015
Key mediators of inflammation including interleukin-6 receptor (IL-6R) and tumor necrosis factor (TNF-α) are substrates of ADAM17.
T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX.
Su et al., Chapel Hill, United States. In Immunity, 28 Oct 2015
UTX-deficient T cells showed decreased expression of interleukin-6 receptor-α and other Tfh cell-related genes that were associated with increased H3K27 methylation.
Novel insights into IL-6 cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex.
Ferlin et al., Saudi Arabia. In J Biol Chem, 11 Oct 2015
UNASSIGNED: The IL-6 signaling complex is described as a hexamer, formed by the association of two IL-6/IL-6R/gp130 trimers, with gp130 being the signal transducer inducing cis- and trans-mediated signaling via a membrane-bound (mb) or soluble (s) form of the IL-6R, respectively.
Shedding of endogenous Interleukin-6 receptor (IL-6R) is governed by ADAM proteases while a full-length IL-6R isoform localizes to circulating microvesicles.
Rabe et al., Kiel, Germany. In J Biol Chem, 10 Oct 2015
UNASSIGNED: Generation of the soluble Interleukin-6 receptor (sIL-6R) is a prerequisite for pathogenic IL-6 trans-signaling, which constitutes a distinct signaling pathway of the pleiotropic cytokine Interleukin-6 (IL-6).
RAID3 - An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.
Hahn et al., Hamburg, Germany. In Rna Biol, 02 Oct 2015
Here we report the selection, characterization and post-selective modification of a 34 nucleotide (nt) RNA aptamer for a non-dominant, novel target site (domain 3) of the interleukin-6 receptor (IL-6R).
Biological agents and respiratory infections: Causative mechanisms and practice management.
Takayanagi, Kumagaya, Japan. In Respir Investig, 30 Sep 2015
In Japan, currently approved biological agents for patients with rheumatoid arthritis (RA) include tumor necrosis factor inhibitors, interleukin-6 receptor-blocking monoclonal antibody, and T-cell costimulation inhibitor.
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Rose-John et al., Kiel, Germany. In Curr Opin Immunol, Jun 2015
However, a plethora of studies in the last decade has convincingly shown that only signaling via the soluble IL-6R (trans-signaling) accounts for the deleterious effects of IL-6, whereas classic signaling via the membrane-bound receptor is essential for the regenerative and anti-bacterial effects of IL-6 (classic signaling).
Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Östör et al., Cambridge, United Kingdom. In Expert Opin Drug Saf, Mar 2015
INTRODUCTION: Tocilizumab (TCZ), a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, has demonstrated efficacy and tolerability in several large randomized, controlled trials for the treatment of rheumatoid arthritis (RA).
Giant cell arteritis and polymyalgia rheumatica: an update.
Pina et al., Santander, Spain. In Curr Rheumatol Rep, Feb 2015
Unlike methotrexate and tumor necrosis factor-α antagonists, anti-interleukin-6 receptor therapy appears to be useful in patients with GCA and PMR who are refractory to corticosteroids.
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Hill et al., Brisbane, Australia. In Lancet Oncol, Dec 2014
Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways.
MiR-125a-5p Decreases the Sensitivity of Treg cells Toward IL-6-Mediated Conversion by Inhibiting IL-6R and STAT3 Expression.
Li et al., Shanghai, China. In Sci Rep, Dec 2014
miR-125a-5p expression is low in Treg cells under steady state conditions and can be induced by GATA-3 to inhibit the expression of IL-6R and STAT3.
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
Mauri et al., Udine, Italy. In Nat Med, Nov 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Grupp et al., Australia. In N Engl J Med, Nov 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Weiss et al., Toronto, Canada. In Nat Rev Immunol, 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends